Find Clinical Trial
Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation, in patients with stable coronary artery disease. A 6 to 12-month randomised double blind parallel groups multicentre study
← Back
| Study Phase |
Phase 3 |
| Therapeutic Area |
Cardiovascular Diseases |
| Indication | Coronary Artery Disease |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S) |
| Active substance/ Medical device |
IVABRADINE, |
| Active Substance Code | S016257 |
| Protocol Code | CL3-16257-097 |
| EudraCT Code | 2012-001668-31 |
Documents and links
| Results summary | READ MORE  |
| Scientific publication | READ MORE |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
